Prestige Consumer Healthcare Inc (PBH) Receives $34.80 Average Price Target from Analysts

Prestige Consumer Healthcare Inc (NYSE:PBH) has received a consensus recommendation of “Hold” from the five analysts that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating and three have issued a hold rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $34.80.

Several equities research analysts have recently issued reports on PBH shares. Raymond James lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating and set a $28.40 price target for the company. in a report on Tuesday, January 15th. ValuEngine cut Prestige Consumer Healthcare from a “hold” rating to a “sell” rating in a research report on Friday, November 16th. Zacks Investment Research cut Prestige Consumer Healthcare from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Finally, DA Davidson raised their price objective on Prestige Consumer Healthcare to $38.00 and gave the company a “neutral” rating in a research report on Monday, November 5th.

NYSE:PBH traded up $0.40 during trading hours on Wednesday, hitting $27.91. The stock had a trading volume of 6,073 shares, compared to its average volume of 703,913. The company has a quick ratio of 1.34, a current ratio of 2.28 and a debt-to-equity ratio of 1.49. Prestige Consumer Healthcare has a 1-year low of $26.25 and a 1-year high of $41.76. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 10.93, a price-to-earnings-growth ratio of 1.60 and a beta of 0.91.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, February 7th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.02. Prestige Consumer Healthcare had a return on equity of 11.85% and a net margin of 6.44%. The company had revenue of $241.40 million for the quarter, compared to analysts’ expectations of $241.40 million. During the same period last year, the business posted $0.70 earnings per share. The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. On average, equities analysts anticipate that Prestige Consumer Healthcare will post 2.76 earnings per share for the current year.

In other Prestige Consumer Healthcare news, EVP Timothy Connors sold 34,000 shares of Prestige Consumer Healthcare stock in a transaction dated Monday, November 19th. The stock was sold at an average price of $38.25, for a total transaction of $1,300,500.00. Following the transaction, the executive vice president now directly owns 25,775 shares of the company’s stock, valued at approximately $985,893.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.14% of the stock is currently owned by insiders.

Several hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC grew its position in Prestige Consumer Healthcare by 6.9% in the 3rd quarter. SG Americas Securities LLC now owns 23,515 shares of the company’s stock worth $891,000 after purchasing an additional 1,525 shares during the period. LSV Asset Management grew its position in Prestige Consumer Healthcare by 7.4% in the third quarter. LSV Asset Management now owns 173,741 shares of the company’s stock valued at $6,583,000 after acquiring an additional 11,900 shares in the last quarter. Icon Advisers Inc. Co. grew its position in Prestige Consumer Healthcare by 82.9% in the third quarter. Icon Advisers Inc. Co. now owns 77,200 shares of the company’s stock valued at $2,925,000 after acquiring an additional 35,000 shares in the last quarter. Rice Hall James & Associates LLC acquired a new stake in Prestige Consumer Healthcare in the third quarter valued at approximately $4,305,000. Finally, Raymond James & Associates grew its position in Prestige Consumer Healthcare by 36.1% in the second quarter. Raymond James & Associates now owns 45,163 shares of the company’s stock valued at $1,733,000 after acquiring an additional 11,989 shares in the last quarter.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.

Featured Article: How to use beta for portfolio diversification

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply